Here we examine the accuracy of exoRNA to predict tissue expression of the prostate cancer-related gene fusion TMPRSS2:ERG (T:E) as well as determine the ability of biomarkers to differentiate prostate cancer-positive (BxPos) from prostate cancer-negative (BxNeg) patients. This evidence concerns the gene ERG and prostate carcinoma.